(Hypertension. 1999;34:491-495.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
From the Dipartimento Cardiotoracico (R.P., G.D., M.M.), Diabetologia (G.P., S.B., R.N.), Medicina Interna (D.G., V.D.), Universita' di Pisa, Italy.
| Abstract |
|---|
|
|
|---|
Key Words: albuminuria hypertension, essential cardiac mass blood pressure capillary permeability
| Introduction |
|---|
|
|
|---|
To bridge the gap, we studied the behavior of the transcapillary escape rate of albumin (TERalb, the fraction of the intravascular mass of albumin passing through the vascular bed per unit time), a parameter determined by the permeability surface area product for macromolecules and the filtration power across the vascular wall and that estimates the integrity of the systemic capillary network.11 TERalb was evaluated in relation to UAE and other cardiovascular and metabolic variables in a group of uncomplicated essential hypertensive patients, who were or were not microalbuminuric.
| Methods |
|---|
|
|
|---|
According to institutional guidelines, subjects were aware of the investigational nature of the study and agreed to participate. The study was performed in accordance with the Declaration of Helsinki, and the protocol was approved by the local ethical committee.
Experimental Procedures
125I-labeled human serum albumin
(6 to 8 µCi [222 to 296 kBq]; SARI-125 A-2, SORIN Biomedica) was
bolus injected after the patient had a 30-minute rest in the sitting
position, and blood was withdrawn from the contralateral arm every 5
minutes during the hour after the injection, as
described.12 Radioactivity was measured (Cobra 5000
-counter; Packard) in duplicate in whole blood samples
centrifuged for 10 minutes at 3000g for 40 minutes.
Hematocrit (Coulter Counter 55; Coulter Electronics) was determined in
each sample by micromethod (intra-assay variation coefficient,
1.5±0.4%, SD) without any consistent change, which indicated
a stable plasma volume throughout the 1-hour period of sampling.
Baseline serum albumin was measured by immunonephelometry
(Behring Laser Nephelometer System, Behring; intra-assay variation
coefficient, 5.2%) immediately before tracer injection.
125I labeling was obtained by electrolytic
technique, a procedure that does not alter the biological behavior of
albumin in vivo.13 Radioiodinated
tracer batches were eluted from free 125I through
passage in Sephadex G 25 mol/L columns (Column PD-10; Pharmacia), a
purification step that reduces free 125I content
in the injected dose to <1%; repeatability studies had also shown a
mean 8.3% intrasubject variation coefficient of
TERalb determination.12
At variance with the original studies performed in the morning after overnight fasts,12 we decided for technical reasons to run these studies between 2 and 4 PM after the subjects underwent a 4-hour fast, with no tea, coffee, alcohol, or tobacco since early morning. The influence of this protocol modification was studied in 5 normal men (age, 28±3 years) in whom measurements were obtained in both experimental conditions at 1-week intervals. TERalb determinations averaged 7.6±0.8%/h in the early afternoon versus 5.6±0.6%/h in the morning sessions (P<0.03 by paired t test). The latter figure was comparable to our previous results obtained in normal controls studied under the same experimental conditions (5.16±1.09%/h).12
UAE was measured by nephelometry (Behring; limit of detection, 0.1 mg/dL; interassay variation coefficient, 3.5%) on overnight samples collected from 8 PM to 8 AM during 3 consecutive days.14 Wall thickness and chamber volumes were determined by monodimensional and bidimensional echocardiograms (Hewlett Packard Sonos 1000) with 2.5- and 3.5-MHz transducers.15 BP was measured through an automated oscillometric device (SpaceLabs 90207, SpaceLabs) every 8 minutes throughout a 2-hour interval during the TERalb procedure.
Anthropometric measurements (height and weight) were performed after each participant had removed his shoes and upper garments. Blood samples were obtained between 8 and 9 AM after an overnight fasting and 15 minutes of supine rest. Total cholesterol, HDL cholesterol, and triglycerides were assessed by enzymatic colorimetric techniques (Boehringer-Mannheim). Serum and urine creatinine levels were assayed by standard colorimetric methods.
Data Analysis
Plasma 125I-labeled albumin
concentration (cpm/mL) was plotted on a semilogarithmic scale, and the
transcapillary escape rate (%/h) was calculated from the
monoexponential disappearance rate constant of the
125I curve from 10 to 60 minutes.12
Only linear regression values with a correlation coefficient of
0.85
were accepted. UAE (µg/min) was the average of 3 consecutive
overnight collections (median variation coefficient of the triplets,
22%; range, 0.5% to 127%). Microalbuminuria was defined
as a value between 15 and 150 µg/min16 ; 2 patients with
UAE of 162 and 190 µg/min were included in the analysis. BP
values were the arithmetic mean of
12 readings after artifact
editing. Plasma volume (mL/1.73 m2) was
determined by retropolation to zero time of the disappearance curve
corrected for the injected dose of tracer obtained by weighing the
syringes before and after the injection. BMI (body weight/squared
surface area), creatinine clearance, and LDL
cholesterol [total cholesterol-(HDL
cholesterol+triglyceride/5)] were derived from
standard formulas. Left ventricular mass (Penn convention)
was corrected for body surface area to derive the left
ventricular mass index (LVMI)
(g/m2).
Statistical Analysis
Log transformation was applied to raw data not distributed
normally. Descriptive statistics were expressed as mean±SD or median
(range) for skewed data. Differences among means were tested by 1-way
ANOVA, and a multiple range test was used to evaluate differences
between means. Intraindividual association of variables was tested
by Pearson's correlation coefficients. Statistical significance was
set at P<0.05. Calculations were performed by the use of
Statgraphics Plus (release 1997, Manugistic Inc).
| Results |
|---|
|
|
|---|
|
Transcapillary Escape Rate of Albumin
TERalb was higher (9.6±2.7%/h [n=73]
versus 6.9±1.2%/h [n=21]; P<0.0001) in hypertensive
patients than in normotensive controls. TERalb
did not differ between normoalbuminuric and
microalbuminuric patients (Figure 1).
|
BP and Left Ventricular Mass
Thicker interventricular septum and posterior wall,
superimposable end-diastolic diameter, and higher
LVMI characterized patients from controls (Table 2). Systolic and, somewhat less
consistently so (P<0.1), diastolic BP
and LVMI were greater in microalbuminuric than in
normoalbuminuric hypertensive subjects (Figure 2 and Table 2).
|
|
Correlations
TERalb and UAE values were unrelated
parameters (Figure 3), even
when the 2 patient subgroups (normoalbuminuric patients:
r=-0.06; n=53; microalbuminuric patients:
r=-0.13; n=20) were analyzed separately. Among the
continuous variables listed in Tables 1 and 2, only
systolic (r=0.38, P<0.002; n=94) and, to
a lesser extent, diastolic (r=0.22,
P<0.03; n=94) BP correlated with
TERalb. Higher UAE values were associated with
more elevated BP (systolic: r=0.43,
P<0.00001; diastolic: r=0.25,
P<0.01; n=94) and LVMI (r=0.28,
P<0.006; n=94).
|
| Discussion |
|---|
|
|
|---|
It was important to be able to reproduce the
TERalb values previously reported by us in normal
subjects12 because this indicates the validity of the
radioiodinated tracer. Therefore, nontechnical reasons, eg,
circadian rhythms or accelerated lymph flow,26 may explain
the slightly higher normal TERalb measured in the
early afternoon after only 4 hours of abstinence from food. These
considerations are to be remembered when our data are compared with
those obtained by other investigators performing the technique under
conditions of more prolonged fasting. Still, this discrepancy does not
invalidate the present conclusions because the same strictly
standardized protocol was applied to both patients and controls. It is
also relevant to highlight the contrast between our data and those
obtained in diabetes,11 12 27 a difference probably
explained by the peculiar characteristics of that disease, as well as
in acute infections28 and high altitude
ascent,29 stressful conditions that differ markedly from
stable, uncomplicated mild-moderate essential hypertension. Other,
albeit somewhat more speculative, possibilities can also be
hypothesized. Similar to the explanation put forward for the lack of
differences in TERalb between patients with
diabetic and incipient nephropathy,27 a
ceiling may exist for the transcapillary albumin
escape rate11 that hypertension per se might maximally
accelerate, thus obscuring any further vascular leak associated with
microalbuminuria. This hypothesis is supported by in vitro
models that predict marked increases in macromolecular transport even
when the capillary wall is only minimally altered,30 but
the relevance of this model to the human situation is unknown. Type of
previous antihypertensive medication31 or the length of
treatment might have affected the transcapillary leakage of
albumin, although this is an unlikely possibility because the
majority of our patients had never been treated and the others were
studied after an appropriate drug withdrawal period. It might even be
speculated whether increased albuminuria in the presence of
abnormal glomerular permselectivity might be obscured by
compensation of other renal control mechanisms, such as modulation of
afferent and efferent arteriolar tone, and mesangial cell
contractility modifications that may change surface
filtration area.32 Confounding from circadian variability
in UAE might also play some role, because albuminuria and
TERalb were measured at different times of the
day, but our data cannot provide data in favor of or against any of the
above possibilities. As a final point, ex post facto calculation
of statistical power showed that our sample size (53
normoalbuminuric versus 20 microalbuminuric patients)
had the statistical power to exclude safely (ß<0.20) differences in
TERalb
1.9%/h. Figures lower than that limit
could not be identified safely, a limitation to be taken into
account.
Transcapillary Albumin Leakage in
Essential Hypertension
Our results confirm33 the influence of systemic BP
levels, more the systolic than the diastolic
component in this particular sample, on TERalb, a
parameter influenced by the permeability surface area
product for macromolecules and the filtration power across the
vascular wall. Hypertension may increase capillary
pressure,34 and acute elevation in systemic perfusion
pressure may accelerate hyperfiltration,35 although other
data are not consistent with this hypothesis.36 On
the other hand, the correlation with BP did not explain the largest
part of TERalb variability, which suggested the
influence of additional factors on the abnormal vascular
albumin permeation. Both larger surface capillary area in which
most of the albumin exchange takes place,11 and
plasma volume expansion37 might play a role, but the
capillary network seems rarefied in hypertension,38
although plasma volume was normal in our patients. Increased
permeability of vascular endothelium, perhaps in the
context of the endothelial dysfunction described in
some hypertensive patients,39 is also to be taken into
account. However, it is impossible to be more specific because
transcapillary macromolecular transport is a complex
phenomenon, and hypertension might damage each of several different
pathways, such as diffusion through endothelial cell
membranes, passage via intercellular junctions,
transendothelial channels of organs and tissues with
highly different permeability, and surface area
products.40
In conclusion, systemic capillary permeability is altered in essential hypertensives, but this abnormality is not reflected by proportionate changes in albuminuria, in contrast to the hypothesis that the augmented urinary albumin leak through the glomerular capillaries reflects a greater perturbation of systemic microvascular permeability in chronic essential hypertension.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received April 16, 1999; first decision May 7, 1999; accepted May 13, 1999.
| References |
|---|
|
|
|---|
2. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Clausen P, Appleyard M, Jensen G. Microalbuminuria and its relation to cardiovascular disease and risk factors: a population-based study of 1254 hypertensive individuals. J Hum Hypertens. 1997;11:727732.[Medline] [Order article via Infotrieve]
3. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens. 1998;16:13251333.[Medline] [Order article via Infotrieve]
4. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects: Islington Diabetes Survey. Lancet. 1988;2:530533.[Medline] [Order article via Infotrieve]
5. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as a predictor of increased mortality in elderly people. BMJ. 1990;300:297300.
6.
Kuusisto J, Mykkanen L, Pyorala K, Laakso M.
Hyperinsulinemic microalbuminuria: a new
risk indicator for coronary heart disease.
Circulation. 1995;91:831837.
7.
Mykkanen L, Zaccaro DJ, O'Leary DH, Howard G, Robbins
DC, Haffner SM. Microalbuminuria and carotid artery
intima-media thickness in nondiabetic and NIDDM subjects: the Insulin
Resistance Atherosclerosis Study (IRAS).
Stroke. 1997;28:17101716.
8. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia.. 1989;32:219226.[Medline] [Order article via Infotrieve]
9. Chobanian A. Overview: hypertension and atherosclerosis. Am Heart J. 1988;116(pt 2):319322.
10. Pedrinelli R. Microalbuminuria in essential hypertension: a marker of systemic vascular damage? Nephrol Dial Transplant.1997;12:379381.
11. Parving HH. Microvascular permeability to plasma proteins in hypertension and diabetes mellitus in man: on the pathogenesis of hypertensive and diabetic microangiopathy. Dan Med Bull. 1975;22:217233.[Medline] [Order article via Infotrieve]
12. Nannipieri M, Pilo A, Rizzo L, Penno G, Rapuano A, Navalesi R. Increased transcapillary escape rate of albumin in microalbuminuric type II diabetic patients. Diabetes Care. 1995;18:19.[Abstract]
13. Rosa U, Pennisi F, Bianchi R, Federighi G, Donato L. Chemical and biological effects of iodination on human albumin. Biochim Biophys Acta. 1967;133:486498.[Medline] [Order article via Infotrieve]
14. Pedrinelli R, Giampietro O, Carmassi O, Melillo E, Dell'Omo G, Catapano G, Matteucci E, Talarico L, Morale M, De Negri F, Di Bello V. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994;344:1418.[Medline] [Order article via Infotrieve]
15.
Pedrinelli R, Bello VD, Catapano G, Talarico L,
Materazzi F, Santoro G, Giusti C, Mosca F, Melillo E, Ferrari M.
Microalbuminuria is a marker of left
ventricular hypertrophy but not
hyperinsulinemia in nondiabetic atherosclerotic
patients. Arterioscler Thromb. 1993;13:900906.
16. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Jensen G, for the Copenhagen City Heart Study Group. Urinary albumin excretion in a population based sample of 1011 middle aged non-diabetic subjects. Scand J Clin Lab Invest. 1993;53:867872.[Medline] [Order article via Infotrieve]
17. Pedrinelli R, Penno G, Dell'Omo G, Bandinelli S, Giorgi D, Di Bello V, Nannipieri M, Navalesi R, Mariani M. Transvascular and urinary leakage of albumin in atherosclerotic and hypertensive men. Hypertension. 1998;32:312318.
18. Pedrinelli R. Microalbuminuria in hypertension. Nephron. 1996;73:499505.[Medline] [Order article via Infotrieve]
19. Hoogenberg K, Sluiter WJ, Navis G, Van Haeften TW, Smit AJ, Reitsma WD, Dullaart RP. Exogenous norepinephrine induces an enhanced microproteinuric response in microalbuminuric insulin-dependent diabetes mellitus. J Am Soc Nephrol. 1998;9:643654.[Abstract]
20. Christensen CK. Rapidly reversible albumin and beta2-microglobulin hyperexcretion in recent severe essential hypertension. J Hypertens. 1983;1:4551.[Medline] [Order article via Infotrieve]
21.
Mimran A, Ribstein J, DuCailar G. Is
microalbuminuria a marker of early intravascular damage in
essential hypertension? Hypertension.. 1994;23:878883.
22. Pedrinelli R, Lindpaintner K, Dell'Omo G, Napoli V, Di Bello V, De Caterina R, Petrucci R. Urinary albumin excretion and atherosclerosis in essential hypertension. Clin Sci (Colch). 1997;92:4550.[Medline] [Order article via Infotrieve]
23. Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jakobs C, Bouter LM, Donker AJM, Stehouwer CDA. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int. 1998;54:203209.[Medline] [Order article via Infotrieve]
24.
Giampietro O, Matteucci EG, Catapano G, Dell' Omo G,
Talarico L, Di Bello V, Pedrinelli R. Microalbuminuria and
erythrocyte Na+/H+ exchange
in hypertension: hemodynamic and metabolic
correlates. Hypertension. 1995;25:981985.
25. Pedrinelli R, Dell'Omo G, Giampietro O, Giorgi D, Di Bello V, Bandinelli S, Penno G, Mariani M. Dissociation between albuminuria and insulinemia in hypertensive and atherosclerotic men. J Hum Hypertens. 1999;13:129134.[Medline] [Order article via Infotrieve]
26. Bianchi R, Mariani G, Pilo A, Toni MG. Albumin distribution from short-term tracer studies in man. In: Bianchi R, Mariani G, McFarlane AS, eds. Plasma Protein Turnover. Baltimore, Md: University Park Press; 1976:7184.
27. Feldt-Rasmussen B. Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia. 1986;29:282286.[Medline] [Order article via Infotrieve]
28. Davis TM, Suputtamongkol Y, Spencer JL, Ford S, Chienkul N, Schulenburg WE, White NJ. Measures of capillary permeability in acute falciparum malaria: relation to severity of infection and treatment. Clin Infect Dis. 1992;15:256266.[Medline] [Order article via Infotrieve]
29.
Hansen JM, Olsen NV, Feldt-Rasmussen B, Kanstrup IL,
Dechaux M, Dubray C, Richalet JP. Albuminuria and overall
capillary permeability of albumin in acute altitude
hypoxia. J Appl Physiol. 1994;76:19221927.
30. Nir A, Pfeffer R. Transport of macromolecules across arterial wall in the presence of local endothelial injury. J Theor Biol. 1979;81:685711.[Medline] [Order article via Infotrieve]
31. Nielsen FS, Rossing P, Gall MA, Smidt UM, Chen JW, Sato A, Parving HH. Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. Scand J Clin Lab Invest. 1997;57:427434.[Medline] [Order article via Infotrieve]
32. Anderson S, Garcia DL, Brenner BM. Renal and systemic manifestations of glomerular disease. In: Brenner BM, Rector FC, eds. The Kidney. Philadelphia, Pa: WB Saunders; 1991:18311843.
33.
Parving HH, Gyntelberg F. Transcapillary
escape rate of albumin and plasma volume in essential
hypertension. Circ Res. 1973;32:643651.
34. Williams SA, Boolell M, MacGregor GA, Smaje LH, Wasserman SM, Tooke JE. Capillary hypertension and abnormal pressure dynamics in patients with essential hypertension. Clin Sci. 1990;79:58.[Medline] [Order article via Infotrieve]
35. Parving HH, Nielsen SL, Lassen NA. Increased transcapillary escape rate of albumin, IgG, and IgM during angiotensin-IIinduced hypertension in man. Scand J Clin Lab Invest. 1974;34:111118.[Medline] [Order article via Infotrieve]
36.
Shore AC, Sandeman DD, Tooke JE. Effect of an increase
in systemic blood pressure on nailfold capillary pressure in humans.
Am J Physiol. 1993;265:H820H823.
37. Parving HH, Rossing N, Nielsen SL, Lassen NA. Increased transcapillary escape rate of albumin, IgG, and IgM after plasma volume expansion. Am J Physiol. 1974;227:245250.
38. Prasad A, Dunnill GS, Mortimer PS, MacGregor GA. Capillary rarefaction in the forearm skin in essential hypertension. J Hypertens. 1995;13:265268.[Medline] [Order article via Infotrieve]
39. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis. 1997;39:287324.[Medline] [Order article via Infotrieve]
40.
Hinsbergh VWM. Endothelial permeability
for macromolecules: mechanistic aspects of
pathophysiological modulation. Arterioscler
Thromb Vasc Biol. 1997;17:10181023.
This article has been cited by other articles:
![]() |
A. J.M. Rennings, P. Smits, M. W. Stewart, and C. J. Tack Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. Diabetes Care, March 1, 2006; 29(3): 581 - 587. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Hillege, V. Fidler, G. F.H. Diercks, W. H. van Gilst, D. de Zeeuw, D. J. van Veldhuisen, R. O.B. Gans, W. M.T. Janssen, D. E. Grobbee, P. E. de Jong, et al. Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population Circulation, October 1, 2002; 106(14): 1777 - 1782. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pedrinelli, G. Dell'Omo, G. Penno, and M. Mariani Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease Vascular Medicine, November 1, 2001; 6(4): 257 - 264. [Abstract] [PDF] |
||||
![]() |
L. DeMaio, Y. S. Chang, T. W. Gardner, J. M. Tarbell, and D. A. Antonetti Shear stress regulates occludin content and phosphorylation Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H105 - H113. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |